Back

Impact of GDMT implementation on albuminuria in HFrEF

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Novel treatment approaches in heart failure and cardiomyopathies Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Noel Panagiotides

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Impact of rhythm control in wild-type transthyretin cardiac amyloidosis and atrial fibrillation: a retrospective analysis
Doctor J. Vogel (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Clinical features of chronic active myocarditis in patients with heart failure and reduced left ventricular ejection fraction
Doctor M. Ruiz Cano (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
Apical sparing and clinical parameters in patients with histologically confirmed transthyretin amyloidosis
Mr T. Krammer (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
Impact of tafamidis on sleep-disordered breathing in transthyretin cardiomyopathy
Miss Y. Ferrari Chen (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and an eGFR below 30 ml/min/1.73 m2
Ms J. Locatelli Bet (Rio Do Sul, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Novel treatment approaches in heart failure and cardiomyopathies

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Kidney function trajectories before and after heart failure hospitalization in heart failure with reduced ejection fraction: findings from clinical trials and real-world data
thumbnail
Congress Presentation
Symptomatic hypotension and worsening renal function according to guideline directed medical therapy levels in high-risk heart failure patients.
thumbnail
Congress Presentation
Factors limiting up-titration only concern a fraction of advanced HFrEF patients and might improve over time

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources